Amgen Inc. (AMGN)
Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease
Data from a late-stage study shows that treatment with Amgen's (AMGN) Uplizna achieves a statistically significant reduction in the risk of flares in patients with IgG4-RD, a rare disease.
Amgen's drug meets main goal in late-stage study for rare disease
Amgen said on Wednesday its drug to treat patients with an immune system-related condition has met the main goal of a late-stage study.
Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
The obesity market is expected to reach $130 billion by 2030, benefiting companies like Eli Lilly and Novo Nordisk. Amgen, a biotech company, is experiencing innovation-fueled growth with impressive new products and international expansion. Amgen offers shareholder value with a strong financial performance, dividend hikes, and a favorable valuation.
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Eli Lilly and Novo Nordisk aren't the only ones making anti-obesity drugs. Amgen, AstraZeneca, and Viking Therapeutics have credible candidates.
Where Will Amgen Be in 3 Years?
Amgen has some compelling late-stage programs in its pipeline. Growth is likely to accelerate as the biotech makes progress.
Amgen's rare-disease treatment biosimilar Bkemv gets FDA approval
Pharmaceutical regulators approved Amgen's AMGN, -1.85% Bkemv, a biosimilar to rare-disease treatment Soliris.
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Amgen has a promising entrant in the anti-obesity therapies space. Its candidate is in phase 2 trials, but there are already plans for phase 3.
Amgen Stock: Poised To Break Out (Technical Analysis)
Amgen Inc. stock is challenging the $320 resistance level after a recent uptrend. Technical indicators suggest short-term upward momentum and strong buying pressure. EPS growth outlook and robust pipeline support the Amgen breakout from a fundamental level.
7 Reliable Blue-Chip Stocks That Cannot Miss
If you're on the hunt for reliable blue-chip stocks to buy this month, look no further. Reliability is one of the most important factors when creating a winning investment strategy.
Amgen, Inc. (AMGN) ATS and the Approval of IMDELLTRA Conference - (Transcript)
Amgen, Inc. (NASDAQ:AMGN ) ATS and the Approval of IMDELLTRA Conference Call May 20, 2024 4:00 PM ET Company Participants Justin Claeys - Vice President of Investor Relations Murdo Gordon - Executive Vice President, Global Commercial Operations James Bradner - Executive Vice President, Research and Development Jean-Charles Soria - Senior Vice President, Global Development Oncology Susan Sweeney - Senior Vice President, Global Marketing, Access Capabilities Primal Kaur - Vice President, Global Development, Inflammation Conference Call Participants Mohit Bansal - Wells Fargo Matt Phipps - William Blair Carter Gould - Barclays Michael Yee - Jefferies Matthew Dellatorre - Goldman Sachs Evan Seigerman - BMO Capital Markets Geoff Meacham - Bank of America James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities Gary Nachman - Raymond James Operator My name is Julianne and I'll be your conference facilitator today for Amgen's Conference Call Following The American Thoracic Society 2024 International Conference and the Approval of IMDELLTRA. All lines have been placed on mute to prevent any background noise.
